BioVersys, a leading Swiss biotech company focused on developing antibacterial products for serious infections, has taken a significant step by listing on the Swiss stock exchange, known as SIX Swiss Exchange. With an opening price of 36.50 Swiss francs per share, the company has reached an estimated market capitalization of 216 million Swiss francs.
This event represents a significant milestone in BioVersys’ journey, evolving from its beginnings as a startup in Basel to becoming a publicly traded entity. The successful Initial Public Offering (IPO) not only marks a major advancement for the company, but also highlights the Swiss stock exchange as a leader in the life sciences sector in Europe, consolidating Switzerland as a global hub for biotechnology innovation.
BioVersys’ issued and outstanding share capital consists of 3,692,285 registered shares, of which 2,222,221 are new shares offered during the IPO. The issuance of these shares at a price of 36 Swiss francs has generated a placement volume close to 80 million Swiss francs, including an overallotment option of 138,888 shares.
The company has stated that the majority of the proceeds from the IPO will be used to advance its lead product, BV100, an antibiotic developed to combat hospital-acquired infections, to Phase III clinical development. In addition, BioVersys will be included in the Swiss Performance Index (SPI) benchmark.
Marc Gitzinger, CEO of BioVersys, expressed his enthusiasm for this achievement: “Today marks a major milestone for BioVersys, taking a step forward in our growth strategy. The positive demand and strong investor interest greatly motivate us. This support will allow us to swiftly progress with our clinical trials and our pipeline of new medicines, in our commitment to bring urgently needed antibiotics to critically ill patients worldwide.”
Meanwhile, Bjørn Sibbern, CEO of SIX, also celebrated BioVersys’ IPO, emphasizing that it kicks off the offering season on the stock exchange and underscores biotech companies’ preference for listing in Switzerland. “This event demonstrates that the country offers an attractive environment for the growth and success of companies in the life sciences. We are proud to support BioVersys in this new chapter.”
Referrer: MiMub in Spanish
